Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  • Anne Tierens
  • Elizabeth Bjørklund
  • Sanna Siitonen
  • Hanne Vibeke Marquart
  • Gitte Wulff-Juergensen
  • Tarja-Terttu Pelliniemi
  • Erik Forestier
  • Henrik Hasle
  • Kirsi Jahnukainen
  • Birgitte Lausen
  • Olafur G Jonsson
  • Josefine Palle
  • Bem Zeller
  • Linda Fogelstrand
  • Jonas Abrahamsson
Vis graf over relationer

Early response after induction is a prognostic factor for disease outcome in childhood acute myeloid leukaemia (AML). Residual disease (RD) detection by multiparameter flow cytometry (MFC) was performed at day 15 and before consolidation therapy in 101 patients enrolled in the Nordic Society of Paediatric Haemato-Oncology AML 2004 study. A multicentre laboratory approach to RD analysis was used. Event-free survival (EFS) and overall survival (OS) was significantly different in patients with and without RD at both time points, using a 0·1% RD cut-off level. RD-negative and -positive patients after first induction showed a 5-year EFS of 65 ± 7% and 22 ± 7%, respectively (P < 0·001) and an OS of 77 ± 6% (P = 0·025) and 51 ± 8%. RD-negative and -positive patients at start of consolidation therapy had a 5-year EFS of 57 ± 7% and 11 ± 7%, respectively (P < 0·001) and an OS of 78 ± 6% and 28 ± 11%) (P < 0·001). In multivariate analysis only RD was significantly correlated with survival. RD before consolidation therapy was the strongest independent prognostic factor for EFS [hazard ratio (HR):5·0; 95% confidence interval (CI):1·9-13·3] and OS (HR:7·0; 95%CI:2·0-24·5). In conclusion, RD before consolidation therapy identifies patients at high risk of relapse in need of intensified treatment. In addition, RD detection can be performed in a multicentre setting and can be implemented in future trials.

TidsskriftBritish Journal of Haematology
Udgave nummer4
Sider (fra-til)600-9
Antal sider10
StatusUdgivet - aug. 2016

ID: 49162256